Abstract
5-Azacytidine was first synthesized almost 40 years ago. It was demonstrated to have a wide range of anti-metabolic activities when tested against cultured cancer cells and to be an effective chemotherapeutic agent for acute myelogenous leukemia. However, because of 5-azacytidine's general toxicity, other nucleoside analogs were favored as therapeutics. The finding that 5-azacytidine was incorporated into DNA and that, when present in DNA, it inhibited DNA methylation, led to widespread use of 5-azacytidine and 5-aza-2′-deoxycytidine (Decitabine) to demonstrate the correlation between loss of methylation in specific gene regions and activation of the associated genes. There is now a revived interest in the use of Decitabine as a therapeutic agent for cancers in which epigenetic silencing of critical regulatory genes has occurred. Here, the current status of our understanding of the mechanism(s) by which 5-azacytosine residues in DNA inhibit DNA methylation is reviewed with an emphasis on the interactions of these residues with bacterial and mammalian DNA (cytosine-C5) methyltransferases. The implications of these mechanistic studies for development of less toxic inhibitors of DNA methylation are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aasland R, Gibson TJ, Stewart AF . 1995 TIBS 20: 56–59
Ammanamanchi S, Brattain MG . 2001 J. Biol. Chem. 276: 32854–32859
Aoki A, Suetake I, Miyagawa J, Fujio T, Chijiwa T, Sasaki H, Tajima S . 2001 Nucleic Acids Res. 29: 3506–3512
Arapshian A, Kuppumbatti YS, Mira-y-Lopez R . 2000 Oncogene 19: 4066–4070
Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F . 2001 Oncogene 20: 7573–7577
Bachman KE, Rountree MR, Baylin SB . 2001 J. Biol. Chem. 276: 32282–32287
Barletta JM, Rainier S, Feinberg AP . 1997 Cancer Res. 57: 48–50
Barlow DP . 1995 Science 270: 1610–1613
Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG . 2001 Hum. Mol. Genet. 10: 687–692
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Beisler JA . 1978 J. Med. Chem. 21: 204–208
Bhagwat AS, Roberts RJ . 1987 J. Bacteriol. 169: 1537–1546
Bird AP . 1986 Nature 321: 209–213
Brank A, Van Bemmel DM, Christman JK . 2002 Protein Expression and Purification 25: 31–40 doi:10.1006/prep.2001.1606
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . 1999 Nat. Genet. 21: 103–107
Chen J, Jones PA . 1990 Cell Growth Differ. 1: 383–392
Cheng X, Roberts RJ . 2001 Nucleic Acids Res. 29: 3784–3795
Christman JK . 1995 Adv. Exp. Med. Biol. 369: 141–154
Christman JK, Chen M-L, Sheikhnejad G, Dizik M, Abileah S, Wainfan E . 1993a J. Nutr. Biochem. 4: 672–680
Christman JK, Mendelsohn N, Herzog D, Schneiderman N . 1983 Cancer Res. 43: 763–769
Christman JK, Price P, Pedrinan L, Acs G . 1977 Eur. J. Biochem. 81: 53–61
Christman JK, Schneiderman N, Acs G . 1985 J. Biol. Chem. 260: 4059–4068
Christman JK, Sheikhnejad G, Dizik M, Abileah S, Wainfan E . 1993b Carcinogenesis 14: 551–557
Christman JK, Sheikhnejad G, Marasco CJ, Sufrin JR . 1995 Proc. Natl. Acad. Sci. USA 92: 7347–7351
Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF . 1997 Science 277: 1996–2000
Chung WY, Yuan L, Feng L, Hensle T, Tycko B . 1996 Hum. Mol. Genet. 5: 1101–1108
Cihak A . 1974 Oncology 30: 405–422
Constantinides PG, Jones PA, Gevers W . 1977 Nature 267: 364–366
Costello JF, Fruhwald MC, Smiraglia D, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C . 2000 Nat. Genet. 24: 132–138
Creusot F, Acs G, Christman JK . 1982 J. Biol. Chem. 257: 2041–2048
Daskalakis M, Nuyen TT, Wijermans P . 1999 Blood 94: 306a
Davidson S, Crowther P, Radley J, Woodcock D . 1992 Eur. J. Cancer 28: 362–368
Dizik M, Christman JK, Wainfan E . 1991 Carcinogenesis 12: 1307–1312
Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G, Zabarovsky ER . 2001 Proc. Natl. Acad. Sci. USA 98: 7504–7509
Ehrlich M . 2000 DNA Alterations in Cancer, Genetic and Epigenetic Changes Ehrlich M (ed) Eton: Natick, MA pp. 273–291
Esteller M, Corn PG, Baylin SB, Herman JG . 2001 Cancer Res. 61: 3225–3229
Fang JY, Zhu SS, Xiao SD, Jiang SJ, Shi Y, Chen XY, Zhou XM, Qian LF . 1996 J. Gastroenterol. Hepatol. 11: 1079–1082
Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M . 1988 Cancer Res. 48: 1159–1161
Feinberg AP, Vogelstein B . 1983 Biochem. Biophys. Res. Commun. 111: 47–54
Feinberg AP, Vogelstein B . 1987 Semin. Surg. Oncol. 3: 149–151
Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S . 2000 Proc. Natl. Acad. Sci. USA 97: 6049–6054
Ferguson AT, Lapidus RG, Baylin SB, Davidson NE . 1995 Cancer Res. 55: 2279–2283
Flatau E, Gonzales FA, Michalowsky LA, Jones PA . 1984 Mol. Cell. Biol. 4: 2098–2102
Friedman S . 1986 Nucleic Acids Res. 14: 4543–4556
Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T . 2000 Nat. Genet. 24: 88–91
Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T . 2001 EMBO J. 20: 2536–2544
Gabbara S, Bhagwat AS . 1995 Biochem. J. 307: 87–92
Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M . 1983 Nucleic Acids Res. 11: 6883–6894
García RG, Brank AS, Christman JK, Marquez VE, Eritja R . 2001 Antisense & Nucleic Acid Drug Development 11: 369–378
Ghoshal AK, Farber E . 1984 Carcinogenesis 5: 1367–1370
Glazer RI, Peale AL, Beisler JA, Abbasi MM . 1980 Mol. Pharmacol. 17: 111–117
Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF . 1987 Cancer Treat. Rep. 71: 737–746
Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP . 1985 Science 228: 187–190
Gowher H, Jeltsch A . 2001 J. Mol. Biol. 309: 1201–1208
Gratchev A, Siedow A, Bumke-Vogt C, Hummel M, Foss HD, Hanski ML, Kobalz U, Mann B, Lammert H, Mansmann U, Stein H, Riecken EO, Hanski C . 2001 Cancer Lett. 168: 71–80
Habuchi T, Luscombe M, Elder PA, Knowles MA . 1998 Genomics 48: 277–288
Halle S . 1968 J. Virol. 2: 1228–1229
Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, Clark G, Steeg PS . 2001 Cancer Res. 61: 2320–2327
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB . 1998 Proc. Natl. Acad. Sci. USA 95: 6870–6875
Hu JF, Nguyen PH, Pham NV, Vu TH, Hoffman AR . 1997 Mol. Endocrinol. 11: 1891–1898
Huynh H, Alpert L, Pollak M . 1996 Cancer Res. 56: 4865–4870
Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 11757–11762
Izbicka E, MacDonald JR, Davidson K, Lawrence RA, Gomez L, Von Hoff DD . 1999 Anticancer Res. 19: 1285–1291
Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R . 1997 Proc. Natl. Acad. Sci. USA 94: 4681–4685
Jhaveri MS, Morrow CS . 1998 Gene 210: 1–7
Jones PA . 1999 Trends Genet. 15: 34–37
Jones PA, Taylor SM . 1980 Cell 20: 85–93
Jones PA, Wolkowicz MJ, Rideout WM, Gonzales FA, Marziasz CM, Coetzee GA . 1990 Proc. Natl. Acad. Sci. USA 87: 6117–6121
Juttermann R, Li E, Jaenisch R . 1994 Proc. Natl. Acad. Sci. USA 91: 11797–11801
Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR . 1997 Clin. Cancer Res. 3: 2025–2032
Karon M, Benedict WF . 1972 Science 178: 62
Karpf AR, Moore BC, Ririe TO, Jones DA . 2001 Mol. Pharmacol. 59: 751–757
Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E, Koeffler HP . 1999 Blood 94: 1113–1120
Klimasauskas S, Kumar S, Roberts RJ, Cheng X . 1994 Cell 76: 357–369
Klimasauskas S, Roberts RJ . 1995 Nucleic Acids Res. 23: 1388–1395
Klimasauskas S, Szyperski T, Serva S, Wuthrich K . 1998 EMBO J. 17: 317–324
Landolph JR, Jones PA . 1982 Cancer Res. 42: 817–823
Lapeyre JN, Becker FF . 1979 Biochem. Biophys. Res. Commun. 87: 698–705
Lapeyre JN, Walker MS, Becker FF . 1981 Carcinogenesis 2: 873–878
Lauster R, Trautner TA, Noyer-Weidner M . 1989 J. Mol. Biol. 206: 305–312
Lee TT, Karon MR . 1976 Biochem. Pharmacol. 25: 1737–1742
Lee YY, Kang SH, Seo JY, Jung CW, Lee KU, Choe KJ, Kim BK, Kim NK, Koeffler HP, Bang YJ . 1997 Cancer 80: 1889–1896
Li LH, Olin EJ, Buskirk HH, Reineke LM . 1970 Cancer Res. 30: 2760–2769
Li Q, Ahuja N, Burger PC, Issa JP . 1999 Oncogene 18: 3284–3289
Lombardi B, Shinozuka H . 1979 Int. J. Cancer 23: 565–570
Lu LJ, Randerath K . 1980 Cancer Res. 40: 2701–2705
Magdinier F, Billard LM, Wittmann G, Frappart L, Benchaib M, Lenoir GM, Guerin JF, Dante R . 2000 Faseb. J. 14: 1585–1594
McGregor DB, Brown AG, Cattanach P, Shepherd W, Riach C, Daston DS, Caspary WJ . 1989 Carcinogenesis 10: 2003–2008
Mendelsohn N, Michl J, Gilbert HS, Acs G, Christman JK . 1980 Cancer Res. 40: 3206–3210
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D . 1995 Nat. Med. 1: 686–692
Mi S, Roberts RJ . 1993 Nucleic Acids Res. 21: 2459–2464
Mikol YB, Hoover KL, Creasia D, Poirier LA . 1983 Carcinogenesis 4: 1619–1629
Mitani H, Yagi T, Leiler CY, Takebe H . 1989 Carcinogenesis 10: 1879–1882
Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J . 1997 Anticancer Drugs 8: 358–368
Momparler RL, Rossi M, Bouchard J, Vaccaro C, Momparler LF, Bartolucci S . 1984 Mol. Pharmacol. 25: 436–440
Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR . 2000 Oncogene 19: 410–416
Myohanen SK, Baylin SB, Herman JG . 1998 Cancer Res. 58: 591–593
Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS . 1997 Cancer Res. 57: 35–37
Newberne PM, Rogers AE . 1986 Annu. Rev. Nutr. 6: 407–432
Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lubbert M, Zhou JH, Benedict WF, Jones PA . 2001 J. Natl. Cancer Inst. 93: 1465–1472
O'Gara M, Klimasauskas S, Roberts RJ, Cheng X . 1996a J. Mol. Biol. 261: 634–645
O'Gara M, Roberts RJ, Cheng X . 1996b J. Mol. Biol. 263: 597–606
O'Gara M, Zhang X, Roberts RJ, Cheng X . 1999 J. Mol. Biol. 287: 201–209
Oshawa K, Imai Y, Ito D, Kohasaka S . 1996 J. Neurochem. 67: 89–97
Paul P . 1982 Kobe J. Med. Sci. 28: 181–196
Piskala A, Sorm F . 1964 Collect Czech Chem. Commun. 29: 2060–2076
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R . 2000 Cancer Res. 60: 6039–6044
Pogribny IP, James SJ . 2002 Cancer Lett. 176: 169–174
Pogribny IP, Pogribna M, Christman JK, James SJ . 2000 Cancer Res. 60: 588–594
Posfai J, Bhagwat AS, Posfai G, Roberts RJ . 1989 Nucleic Acids Res. 17: 2421–2435
Robertson KD . 2001 Oncogene 20: 3139–3155
Robertson KD, Wolffe AP . 2000 Nat. Rev. Genet. 1: 11–19
Rountree MR, Bachman KE, Baylin SB . 2000 Nat. Genet. 25: 269–277
Salem CE, Markl ID, Bender CM, Gonzales FA, Jones PA, Liang G . 2000 Int. J. Cancer 87: 179–185
Santi DV, Norment A, Garrett CE . 1984 Proc. Natl. Acad. Sci. USA 81: 6993–6997
Santini V, Kantarjian HM, Issa JP . 2001 Ann. Intern. Med. 134: 573–586
Sato S, Yokozaki H, Yasui W, Nikai H, Tahara E . 1999 Jpn. J. Cancer Res. 90: 485–489
Sekita N, Suzuki H, Ichikawa T, Kito H, Akakura K, Igarashi T, Nakayama T, Watanabe M, Shiraishi T, Toyota M, Yoshie O, Ito H . 2001 Jpn. J. Cancer Res. 92: 947–951
Sharrard RM, Royds JA, Rogers S, Shorthouse AJ . 1992 Br. J. Cancer 65: 667–672
Sheikhnejad G, Brank A, Christman JK, Goddard A, Alvarez E, Ford Jr H, Marquez VE, Marasco CJ, Sufrin JR, O'Gara M, Cheng X . 1999 J. Mol. Biol. 285: 2021–2034
Shin JY, Kim HS, Park J, Park JB, Lee JY . 2000 Cancer Res. 60: 262–265
Shivapurkar N, Poirier LA . 1983 Carcinogenesis 4: 1051–1057
Silverman AL, Park JG, Hamilton SR, Gazdar AF, Luk GD, Baylin SB . 1989 Cancer Res. 49: 3468–3473
Singal R, Tu ZJ, Vanwert JM, Ginder GD, Kiang DT . 2000 Anticancer Res. 20: 59–64
Sorm F, Piskala A, Cihak A, Vesely J . 1964 Experientia 20: 202–203
Taylor SM, Jones PA . 1979 Cell 17: 771–779
Taylor SM, Jones PA . 1982 J. Mol. Biol. 162: 679–692
Timmermann S, Hinds PW, Munger K . 1998 Oncogene 17: 3445–3453
Vachtenheim J, Horakova I, Novotna H . 1994 Cancer Res. 54: 1145–1148
van Agthoven T, van Agthoven TL, Dekker A, Foekens JA, Dorssers LC . 1994 Mol. Endocrinol. 8: 1474–1483
van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ . 2001 Cancer Res. 61: 5303–5306
Vesely J, Cihak A . 1978 Pharmac. Ther. A. 2: 813–840
Vesely J, Cihak A, Sorm F . 1969 Collect Czech Chem. Commun. 34: 901–909
Viegas-Pequignot E, Dutrillaux B . 1976 Hum. Genet. 34: 247–254
Visvader J, Adams JM . 1993 Blood 82: 1493–1501
Wainfan E, Dizik M, Stender M, Christman JK . 1989 Cancer Res. 49: 4094–4097
Wang P, Brank AS, Nicklaus MC, Marquez VE, Christman JK, Banavali NK, MacKerell AD . 2000 J. Amer. Chem. Soc. 122: 12422–12434
Weiss JW, Pitot HC . 1974 Arch. Biochem. Biophys. 160: 119–129
Wilson VL, Jones PA . 1983 Science 220: 1055–1057
Xing RH, Rabbani SA . 1999 Int. J. Cancer 81: 443–450
Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, Caldwell CW, Huang TH . 2001 Cancer Res. 61: 8375–8380
Yang AS, Shen JC, Zingg JM, Mi S, Jones PA . 1995 Nucleic Acids Res. 23: 1380–1387
Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S . 1995 Proc. Natl. Acad. Sci. USA 92: 7416–7419
Zhang X, Verdine GL . 1996 FEBS Lett. 392: 179–183
Zingg JM, Jones PA . 1997 Carcinogenesis 18: 869–882
Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD . 2001 Cancer Res. 61: 3581–3585
Acknowledgements
I am indebted to my colleagues, Drs AS Brank, X Cheng, R Eritja, VE Marquez and J Sufrin. The research on ODNs discussed here could not have been done without their help. I also thank M Boland and D Van Bemmel for their expert help with the figures. Supported in part by grants R21 CA091315-01 from the National Cancer Institute and DAMD 17-98-1-8215 from the Department of the Army Breast Cancer Program. Additional support came from the Cancer and Smoking Disease Research Program, Nebraska Department of Health, 97-15 and UNMC/Eppley Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Christman, J. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483–5495 (2002). https://doi.org/10.1038/sj.onc.1205699
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205699
Keywords
This article is cited by
-
Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer
Nature Cancer (2024)
-
Antagonistic interactions safeguard mitotic propagation of genetic and epigenetic information in zebrafish
Communications Biology (2024)
-
Comparative analysis of the chrysanthemum transcriptome with DNA methylation inhibitors treatment and silencing MET1 lines
BMC Plant Biology (2023)
-
Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas
Clinical Epigenetics (2023)
-
Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy
Stem Cell Research & Therapy (2023)